Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,944
  • Shares Outstanding, K 53,987
  • Annual Sales, $ 103,780 K
  • Annual Income, $ 22,810 K
  • 60-Month Beta 0.62
  • Price/Sales 0.68
  • Price/Cash Flow 2.52
  • Price/Book 0.87
Trade SPRO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.47
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.55
  • Prior Year 0.02
  • Growth Rate Est. (year over year) -2,450.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1900 +4.20%
on 10/08/24
1.4200 -12.68%
on 09/16/24
-0.1300 (-9.49%)
since 09/09/24
3-Month
1.1500 +7.83%
on 08/19/24
1.5300 -18.95%
on 07/16/24
-0.1150 (-8.49%)
since 07/09/24
52-Week
0.9900 +25.25%
on 10/26/23
1.8900 -34.39%
on 03/14/24
+0.0900 (+7.83%)
since 10/09/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

SPRO : 1.2400 (unch)
Pre-Market Brief: Stocks Mixed as Risk-off Rout Continues

December S&P 500 futures (ESZ22) are trending down -0.17% this morning after three major US benchmark indices ended the previous week at 3-month lows as fears grew that raising interest rates to combat...

ESZ22 : 3,871.47s (-0.66%)
SPRO : 1.2400 (unch)
BUD : 64.27 (+0.06%)
RELI : 2.16 (-4.00%)
SONX : 0.0548 (+0.37%)
ASML : 845.90 (+2.63%)
GOGL : 12.22 (-2.86%)
Markets Today: Stocks Extend This Week’s Plunge on Recession Fears

Morning Markets December S&P 500 futures (ESZ22 ) this morning are down by -1.21% at a 2-month low. Stock indexes this morning are extending this week’s sell-off on concern that the Fed’s resolve to...

ESZ24 : 5,830.75 (-0.18%)
COST : 909.10 (+2.10%)
AMD : 171.02 (-1.03%)
FDX : 264.64 (+1.24%)
ACN : 365.08 (+1.30%)
DVN : 41.96 (+0.67%)
FANG : 193.75 (-0.01%)
XOM : 122.09 (+0.04%)
COP : 110.97 (+0.15%)
HAL : 30.36 (+1.03%)
OXY : 53.90 (-0.77%)
MRO : 28.14 (+0.11%)
Pre-Market Brief: Stocks Lower as Post-Fed Stumble Continues

December S&P 500 futures (ESZ22) are trending down -0.58% this morning after three major US benchmark indices ended in the red for a third straight trading session as investors reacted to the Federal Reserve's...

ESZ22 : 3,871.47s (-0.66%)
SPPI : 1.0300 (unch)
COST : 909.10 (+2.10%)
TTOO : 1.6200 (+3.18%)
SPRO : 1.2400 (unch)
CANO : 2.30 (-2.13%)
HUM : 245.45 (+0.93%)
CVS : 65.97 (+0.11%)
Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr

Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and

SPRO : 1.2400 (unch)
GSK : 40.24 (+5.84%)
Micro Cap Up Over +100% In Premarket

A Massachusetts-based %Biotech firm is grabbing the attention of traders across the board during Thursday’s premarket after it was announced that the company has entered into an exclusive license agreement...

GSK : 40.24 (+5.84%)
SPRO : 1.2400 (unch)
Pre-Market Brief: Stocks Mixed as Fed Signals More Sharp Rate Hikes

December S&P 500 futures (ESZ22) are trending up +0.49% this morning after three major US benchmark indices jolted up and down before plunging in the final 30 minutes of trading to close Wednesday in the...

ESZ22 : 3,871.47s (-0.66%)
SPRO : 1.2400 (unch)
LLY : 919.74 (+0.66%)
CRM : 287.92 (-1.25%)
META : 590.51 (-0.40%)
TCOM : 62.39 (+1.48%)
NVAX : 12.68 (-2.76%)
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of...

SPRO : 1.2400 (unch)
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live...

SPRO : 1.2400 (unch)
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO)...

SPRO : 1.2400 (unch)

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 1.2833
2nd Resistance Point 1.2667
1st Resistance Point 1.2533
Last Price 1.2400
1st Support Level 1.2233
2nd Support Level 1.2067
3rd Support Level 1.1933

See More

52-Week High 1.8900
Fibonacci 61.8% 1.5462
Fibonacci 50% 1.4400
Fibonacci 38.2% 1.3338
Last Price 1.2400
52-Week Low 0.9900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar